Fact based stock research
Mezzion Pharma (KOSDAQ:A140410)
KR7140410002
Mezzion Pharma stock research in summary
Mezzion Pharma shares are more expensive than other comparable stocks. While they show above average growth, they are riskily financed, and are poor value. We recommend evaluating whether the future of the company Mezzion Pharma is really as positive as the high price of the shares suggests. If you come to the conclusion that the future for this company is only average, that could be a reason to sell this share.
Latest Obermatt Ranks
| Value Rank | 1 |  |
| Growth Rank | 76 |  |
| Safety Rank | 10 | |
| Combined Rank | 20 | |
| Country | South Korea |
| Industry | Pharmaceuticals |
| Index | |
| Size class | X-Small |
October 7, 2021. Stock data may be delayed. Login to get the most recent research.
Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Mezzion Pharma from October 7, 2021.
We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.